Collectively, these results suggest that evodiamine-induced ferroptosis in prostate cancer cells may not depend on regulating cellular iron metabolism, but rather on inhibiting the expression of the GPX4 protein. This evidence concerns the gene GPX4 and prostate carcinoma.